Overview
Norway medical device maker's Q1 sales rose 11% yr/yr, topping NOK 200 mln for first time
Company announced dividend of NOK 8.00 per share, totaling NOK 146.2 mln
Outlook
Company did not provide specific guidance or outlook for future quarters or full year in press release
Result Drivers
APAC GROWTH - Currency neutral sales in APAC rose 57.5% in Q1, leading regional performance
AMERICAS GROWTH - Currency neutral sales in Americas grew 30.9% in Q1
Company press release: ID:nObiRpjxDa
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EBIT
NOK 57.10 mln
Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."
Wall Street's median 12-month price target for Medistim ASA is NOK310.00, about 36% above its May 6 closing price of NOK228.00
The stock recently traded at 29 times the next 12-month earnings vs. a P/E of 29 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
